Cost of treating chronic hepatitis B: Comparison of current treatment guidelines

World Journal of Gastroenterology

Volumn 18, Issue 42, 2012, Pages 6106-6113

  Robotin, Monica ^a,b   Patton, Yumi ^a   Kansil, Melanie ^c   Penman, Andrew ^a   George, Jacob ^d,e  

^a CANCER RESEARCH DIVISION   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c Westmead Hospital ^*  (Australia)

^d University of Sydney   (Australia)

^e WESTMEAD HOSPITAL   (Australia)

Author keywords

Chronic hepatitis B; Hepatocellular cancer; Markov model; Treatment guidelines

Indexed keywords

ALANINE AMINOTRANSFERASE;

ADULT; ALGORITHM; ARTICLE; AUSTRALIA; COMPARATIVE STUDY; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; HEALTH CARE COST; HEPATITIS B; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; PRACTICE GUIDELINE; UNITED STATES; VIRUS LOAD;

EID: 84869840941     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v18.i42.6106     Document Type: Article

References (28)

1. Alam N, Chen W, Baker D, Bishop J. Liver Cancer in New South Wales. Sydney: Cancer Institute NSW, 2009. Available from: URL: http://www.cancerinstitute.org.au/publications/i/liver-cancer-in-new-south-wales
2. Amin J, O'Connell D, Bartlett M, Tracey E, Kaldor J, Law M, Dore G. Liver cancer and hepatitis B and C in New South Wales, 1990-2002: a linkage study. Aust N Z J Public Health 2007; 31: 475-482
3. Supramaniam R, O'Connell DL, Tracey E, Sitas F. Cancer incidence in New South Wales migrants 1991 to 2001. Sydney: The Cancer Council NSW, 2006
4. Lavanchy D. Chronic viral hepatitis as a public health issue in the world. Best Pract Res Clin Gastroenterol 2008; 22: 991-1008
5. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, Tanwandee T, Tao QM, Shue K, Keene ON, Dixon JS, Gray DF, Sabbat J. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351: 1521-1531
6. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45: 507-539
7. Papatheodoridis GV, Lampertico P, Manolakopoulos S, Lok A. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. J Hepatol 2010; 53: 348-356
8. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004; 11: 97-107
9. Dore G, Wallace J, Locarnini S, Desmond P, Gane E, Crawford DH. Hepatitis B in Australia: responding to a diverse epidemic. Sydney: Australasian Society for HIV Medicine, 2006. Available from: URL: http://www.ashm.org.au/uploads/Hep-B-in-Australia.pdf
10. Robotin MC, Kansil M, Howard K, George J, Tipper S, Dore GJ, Levy M, Penman AG. Antiviral therapy for hepatitis B-related liver cancer prevention is more cost-effective than cancer screening. J Hepatol 2009; 50: 990-998
11. Sherman M. Prevention of hepatocellular carcinoma: the holy grail of hepatitis B treatment. J Hepatol 2009; 50: 854-856
12. Digestive Health Foundation. Australian and New Zealand chronic hepatitis B (CHB) recommendations. 2nd ed. Melbourne: Digestive Health Foundation, Gastroenterological Society of Australia, 2008
13. European Association For The Study Of The Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009; 50: 227-242
14. Liaw YF, Leung N, Guan R, Lau GK, Merican I, McCaughan G, Gane E, Kao JH, Omata M. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update. Liver Int 2005; 25: 472-489
15. Keeffe EB, Dieterich DT, Han SH, Jacobson IM, Martin P, Schiff ER, Tobias H. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol 2008; 6: 1315-1341; quiz 1286
16. Nguyen VT, Razali K, Amin J, Law MG, Dore GJ. Estimates and projections of hepatitis B-related hepatocellular carcinoma in Australia among people born in Asia-Pacific countries. J Gastroenterol Hepatol 2008; 23: 922-929
17. Robinson T, Bullen C, Humphries W, Hornell J, Moyes C. The New Zealand Hepatitis B Screening Programme: screening coverage and prevalence of chronic hepatitis B infection. N Z Med J 2005; 118: U1345
18. Yuen MF, Yuan HJ, Wong DK, Yuen JC, Wong WM, Chan AO, Wong BC, Lai KC, Lai CL. Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications. Gut 2005; 54: 1610-1614
19. Yuen MF, Yuan HJ, Hui CK, Wong DK, Wong WM, Chan AO, Wong BC, Lai CL. A large population study of spontaneous HBeAg seroconversion and acute exacerbation of chronic hepatitis B infection: implications for antiviral therapy. Gut 2003; 52: 416-419
20. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, Huang GT, Iloeje UH. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65-73
21. Kim HC, Nam CM, Jee SH, Han KH, Oh DK, Suh I. Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study. BMJ 2004; 328: 983
22. Tong MJ, Hsien C, Hsu L, Sun HE, Blatt LM. Treatment recommendations for chronic hepatitis B: an evaluation of current guidelines based on a natural history study in the United States. Hepatology 2008; 48: 1070-1078
23. Hatzakis A, Wait S, Bruix J, Buti M, Carballo M, Cavaleri M, Colombo M, Delarocque-Astagneau E, Dusheiko G, Esmat G, Esteban R, Goldberg D, Gore C, Lok AS, Manns M, Marcellin P, Papatheodoridis G, Peterle A, Prati D, Piorkowsky N, Rizzetto M, Roudot-Thoraval F, Soriano V, Thomas HC, Thursz M, Valla D, van Damme P, Veldhuijzen IK, Wedemeyer H, Wiessing L, Zanetti AR, Janssen HL. The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference*. J Viral Hepat 2011; 18 Suppl 1: 1-16
24. Hutton DW, Tan D, So SK, Brandeau ML. Cost-effectiveness of screening and vaccinating Asian and Pacific Islander adults for hepatitis B. Ann Intern Med 2007; 147: 460-469
25. Veldhuijzen IK, Toy M, Hahné SJ, De Wit GA, Schalm SW, de Man RA, Richardus JH. Screening and early treatment of migrants for chronic hepatitis B virus infection is costeffective. Gastroenterology 2010; 138: 522-530
26. Qian MY, Yuwei J R, Angus P, Schelleman T, Johnson L, Gow P. Efficacy and cost of a hepatocellular carcinoma screening program at an Australian teaching hospital. J Gastroenterol Hepatol 2010; 25: 951-956
27. Hutton DW, Brandeau ML, So SK. Doing Good with Good OR: Supporting Cost-effective Hepatitis B Interventions. Interfaces (Providence) 2011; 41: 289-300
28. Shouval D. Focus: Long-term treatment with lamivudine in HBeAg negative patients with chronic hepatitis B: to switch or not to switch? J Hepatol 2012; 56: 1219-1220